Back to search

Peptide record

TPDB15806

Antibacterial Toxicity modified_plain modified
10 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB15806
Antibacterial Toxicity
Anti-infective peptides Toxicity and safety peptides
dbAMP Peptipedia
modified_plain
Yes
A 10-aa modified multi-activity (Antibacterial and Toxicity) peptide sequence curated from dbAMP and Peptipedia, with an available 3D structural model.
Modified, details unspecified
Sequence
ALWKKLLKKX
Physicochemical Analysis
C56H98N14O10
RNDCEQGHIMFPSTYV
K
1127.48
11.00
4
0
5
+4
0.26
-0.330
127.00
Mammalian: 4.4 hour Yeast: >20 hour E.coli: >10 hour
5500
487.81
0
Residue Composition
number
1
A
0
R
0
N
0
D
0
C
0
E
0
Q
0
G
0
H
0
I
3
L
4
K
0
M
0
F
0
P
0
S
0
T
1
W
0
Y
0
V
Amino Acid Distribution
A: 1 R: 0 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 0 H: 0 I: 0 L: 3 K: 4 M: 0 F: 0 P: 0 S: 0 T: 0 W: 1 Y: 0 V: 0
Chemical Descriptors
10
C56H98N14O10
1127.48
11.00
+4
0.26
-0.330
Evidence Records 7 records
Evidence 1 Activity

Activity

8% Hemolysis
Toxicity
64 µM
Hemolytic Cytotoxic
8% Hemolysis | 64 | µM | target cell: Horse erythrocytes

Target

Horse erythrocytes

Source & Reference

NA
DBAASP
Design of N-Terminal Derivatives from a Novel Dermaseptin Exhibiting Broad-Spectrum Antimicrobial Activity against Isolates from Cystic Fibrosis Patients. | Biomolecules | 2019
Evidence 2 Activity

Activity

18% Hemolysis
Toxicity
128 µM
Hemolytic Cytotoxic
18% Hemolysis | 128 | µM | target cell: Horse erythrocytes

Target

Horse erythrocytes

Source & Reference

NA
DBAASP
Design of N-Terminal Derivatives from a Novel Dermaseptin Exhibiting Broad-Spectrum Antimicrobial Activity against Isolates from Cystic Fibrosis Patients. | Biomolecules | 2019
Evidence 3 Activity

Activity

35% Hemolysis
Toxicity
256 µM
Hemolytic Cytotoxic
35% Hemolysis | 256 | µM | target cell: Horse erythrocytes

Target

Horse erythrocytes

Source & Reference

NA
DBAASP
Design of N-Terminal Derivatives from a Novel Dermaseptin Exhibiting Broad-Spectrum Antimicrobial Activity against Isolates from Cystic Fibrosis Patients. | Biomolecules | 2019
Evidence 4 Activity

Activity

90% Hemolysis
Toxicity
512 µM
Hemolytic Cytotoxic
90% Hemolysis | 512 | µM | target cell: Horse erythrocytes

Target

Horse erythrocytes

Source & Reference

NA
DBAASP
Broad-Spectrum Antimicrobial Activity and Improved Stability of a D-Amino Acid Enantiomer of DMPC-10A, the Designed Derivative of Dermaseptin Truncates. | Antibiotics (Basel) | 2020
Evidence 5 Activity

Activity

57% Killing
Toxicity
8 µM
Cytotoxic
57% Killing | 8 | µM | target cell: Human keratinocytes HaCat

Target

Human keratinocytes HaCat

Source & Reference

NA
DBAASP
Broad-Spectrum Antimicrobial Activity and Improved Stability of a D-Amino Acid Enantiomer of DMPC-10A, the Designed Derivative of Dermaseptin Truncates. | Antibiotics (Basel) | 2020
Evidence 6 Activity

Activity

95% Killing
Toxicity
32-64 µM
Cytotoxic
95% Killing | 32-64 | µM | target cell: Human keratinocytes HaCat

Target

Human keratinocytes HaCat

Source & Reference

NA
DBAASP
Broad-Spectrum Antimicrobial Activity and Improved Stability of a D-Amino Acid Enantiomer of DMPC-10A, the Designed Derivative of Dermaseptin Truncates. | Antibiotics (Basel) | 2020
Evidence 7 Activity

Activity

98% Killing
Toxicity
128 µM
Cytotoxic
98% Killing | 128 | µM | target cell: Human keratinocytes HaCat

Target

Human keratinocytes HaCat

Source & Reference

NA
DBAASP
Broad-Spectrum Antimicrobial Activity and Improved Stability of a D-Amino Acid Enantiomer of DMPC-10A, the Designed Derivative of Dermaseptin Truncates. | Antibiotics (Basel) | 2020